PMID- 34675989
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230630
IS  - 1741-427X (Print)
IS  - 1741-4288 (Electronic)
IS  - 1741-427X (Linking)
VI  - 2021
DP  - 2021
TI  - Levels of Serum sST2, MMP-3, and Gal-3 in Patients with Essential Hypertension 
      and Their Correlation with Left Ventricular Hypertrophy.
PG  - 7262776
LID - 10.1155/2021/7262776 [doi]
LID - 7262776
AB  - Essential hypertension (EH) is a clinically frequent cardiovascular disease, with 
      insidious onset, causing increased pressure load and neuroregulation disorders in 
      patients. Long-term EH can cause left ventricular hypertrophy (LVH), which can 
      lead to arrhythmia and even death. The soluble suppression of tumorigenicity 2 
      (sST2), matrix metalloproteinase-3 (MMP-3), and galectin-3 (Gal-3) in serum plays 
      an important role in the occurrence, development, and prognosis of cardiovascular 
      diseases. In our study, we divided EH patients into 3 levels and groups with or 
      without LVH, according to their condition. The levels of sST2, MMP-3, and Gal-3 
      in the serum were measured in different groups of patients. Our results showed 
      that the levels of sST2, MMP-3, and Gal-3 in the serum increased progressively 
      with the level in different EH groups. The levels of sST2, MMP-3, and Gal-3 in 
      the serum of the LVH group were higher than those of the NLVH group, and it is 
      positively correlated with LVH-related indexes. The risk of developing and 
      progressing to LVH in patients with EH can be determined by the method of 
      measuring three indicators.
CI  - Copyright (c) 2021 Xueling Wang et al.
FAU - Wang, Xueling
AU  - Wang X
AD  - Department of Cardiovascular Medicine, Beijing Hospital of Integrated Traditional 
      Chinese and Western Medicine, Beijing 100039, China.
FAU - Han, Wei
AU  - Han W
AUID- ORCID: 0000-0001-5711-201X
AD  - Department of Cardiovascular Medicine, Beijing Hospital of Integrated Traditional 
      Chinese and Western Medicine, Beijing 100039, China.
FAU - Han, Lin
AU  - Han L
AD  - Department of Cardiology, Beijing Luhe Hospital Affiliated to Capital Medical 
      University, Beijing 101149, China.
FAU - Yang, Jiyuan
AU  - Yang J
AD  - Department of Cardiovascular Medicine, Beijing Hospital of Integrated Traditional 
      Chinese and Western Medicine, Beijing 100039, China.
FAU - Li, Kehui
AU  - Li K
AD  - Department of Cardiovascular Medicine, Beijing Hospital of Integrated Traditional 
      Chinese and Western Medicine, Beijing 100039, China.
FAU - Fan, Yun
AU  - Fan Y
AD  - Department of Cardiology, Beijing Traditional Chinese Medicine Hospital 
      Affiliated to Capital Medical University, Beijing 100010, China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20211012
PL  - United States
TA  - Evid Based Complement Alternat Med
JT  - Evidence-based complementary and alternative medicine : eCAM
JID - 101215021
RIN - Evid Based Complement Alternat Med. 2023 Jun 21;2023:9836951. PMID: 37388056
PMC - PMC8526212
COIS- The authors declare no conflicts of interest, financial, or otherwise.
EDAT- 2021/10/23 06:00
MHDA- 2021/10/23 06:01
PMCR- 2021/10/12
CRDT- 2021/10/22 06:49
PHST- 2021/09/07 00:00 [received]
PHST- 2021/09/24 00:00 [accepted]
PHST- 2021/10/22 06:49 [entrez]
PHST- 2021/10/23 06:00 [pubmed]
PHST- 2021/10/23 06:01 [medline]
PHST- 2021/10/12 00:00 [pmc-release]
AID - 10.1155/2021/7262776 [doi]
PST - epublish
SO  - Evid Based Complement Alternat Med. 2021 Oct 12;2021:7262776. doi: 
      10.1155/2021/7262776. eCollection 2021.